203 related articles for article (PubMed ID: 34635925)
61. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
Yan Y; Gao Z; Han H; Zhao Y; Zhang Y; Ma X; Chen H
J Cancer Res Clin Oncol; 2022 Mar; 148(3):565-575. PubMed ID: 34746975
[TBL] [Abstract][Full Text] [Related]
62. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
[TBL] [Abstract][Full Text] [Related]
63. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
64. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
65. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
[TBL] [Abstract][Full Text] [Related]
66. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
Chen G; Dong Z; Wu D; Chen Y
J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
[TBL] [Abstract][Full Text] [Related]
67. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
[TBL] [Abstract][Full Text] [Related]
68. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration.
Zhou H; Bian T; Qian L; Zhao C; Zhang W; Zheng M; Zhou H; Liu L; Sun H; Li X; Zhang J; Liu Y
Pathol Res Pract; 2021 Dec; 228():153680. PubMed ID: 34798483
[TBL] [Abstract][Full Text] [Related]
69. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
70. TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.
He A; Zhang R; Wang J; Huang Z; Liao W; Li Y; Wang C; Yang J; Feng Q; Wu L
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e129-e140. PubMed ID: 33852776
[TBL] [Abstract][Full Text] [Related]
71. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
72. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
Wu YJ; Nai AT; He GC; Xiao F; Li ZM; Tang SY; Liu YP; Ai XH
World J Surg Oncol; 2021 Sep; 19(1):274. PubMed ID: 34517904
[TBL] [Abstract][Full Text] [Related]
73. Lipid metabolism gene-wide profile and survival signature of lung adenocarcinoma.
Li J; Li Q; Su Z; Sun Q; Zhao Y; Feng T; Jiang J; Zhang F; Ma H
Lipids Health Dis; 2020 Oct; 19(1):222. PubMed ID: 33050938
[TBL] [Abstract][Full Text] [Related]
74. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
75. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
76. Prognostic Risk Signature and Comprehensive Analyses of Endoplasmic Reticulum Stress-Related Genes in Lung Adenocarcinoma.
Yang C; Wei Y; Li W; Wei J; Chen G; Xu M; Liu G
J Immunol Res; 2022; 2022():6567916. PubMed ID: 35571564
[TBL] [Abstract][Full Text] [Related]
77. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
78. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.
Yu L; Qiao R; Xu J; Han B; Zhong R
Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533
[TBL] [Abstract][Full Text] [Related]
79. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma.
Zhang Y; Wang Y; Chen J; Xia Y; Huang Y
Front Immunol; 2023; 14():1183230. PubMed ID: 37671155
[TBL] [Abstract][Full Text] [Related]
80. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]